Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Ian Woolhouse"'
Autor:
Christopher Craig, MBChB, Janet Johnston, M.B.B.S., Patrick Goodley, MB BChir, Paul Bishop, BA, MB BCh, FRCPath, Haider Al-Najjar, MBChB, FRCP, Louise Brown, MD, MRCP, Joanna Gallagher, MBChB, Ramachandran Sundar, M.B.B.S., Sara Upperton, MBChB, Matthew Callister, BM BCh, David Meek, BM, MRCP SCE, Laura Succony, BM, Wadood Parvez, M.B.B.S., Muhammad Tufail, M.B.B.S., FRCP, Geeshath Jayasekera, MBChB, MRCP, PhD, John Maclay, MBChB, Alana Livesey, MB BChir, Ian Woolhouse, M.B.B.S., Natalie Smith, BSc, MBChB, Anna Bibby, MBChB, PhD, Matthew Evison, MD, MRCP, MBChB
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 8, Pp 100694- (2024)
Introduction: Single-station N2 (ssN2) versus multi-station N2 has been used as a selection criterion for treatment recommendations between surgical versus non-surgical multimodality treatment in stage III-N2 NSCLC. We hypothesized that clinical stag
Externí odkaz:
https://doaj.org/article/11bc8eb79e6f403d9c64c4624170c6da
Autor:
Selina Tsim, Janelle Yorke, Ian Woolhouse, John Edwards, Corinne Faivre-Finn, Matthew Evison, Neal Navani, Sally Taylor, Fabio Gomes, Fiona Blackhall, Seamus Grundy, Sarah Rhodes, Jonathan Robson
Publikováno v:
BMJ Open Respiratory Research, Vol 8, Iss 1 (2021)
Introduction Optimal treatment for ‘potentially resectable’ stage III-N2 non-small cell lung cancer (NSCLC) requires multimodality treatment: local treatment (surgery or radiotherapy) and systemic anticancer therapy. There is no clear evidence of
Externí odkaz:
https://doaj.org/article/478979648ae24be18506ec02c119559a
Autor:
Aamir Khakwani, Ruth H. Jack, Sally Vernon, Rosie Dickinson, Natasha Wood, Susan Harden, Paul Beckett, Ian Woolhouse, Richard B. Hubbard
Publikováno v:
ERJ Open Research, Vol 3, Iss 3 (2017)
In 2014, the method of data collection from NHS trusts in England for the National Lung Cancer Audit (NLCA) was changed from a bespoke dataset called LUCADA (Lung Cancer Data). Under the new contract, data are submitted via the Cancer Outcome and Ser
Externí odkaz:
https://doaj.org/article/753322bc76514d9b9d401c78626566de
Autor:
Mariam Jamal-Hanjani, Alan Hackshaw, Yenting Ngai, Jacqueline Shaw, Caroline Dive, Sergio Quezada, Gary Middleton, Elza de Bruin, John Le Quesne, Seema Shafi, Mary Falzon, Stuart Horswell, Fiona Blackhall, Iftekhar Khan, Sam Janes, Marianne Nicolson, David Lawrence, Martin Forster, Dean Fennell, Siow-Ming Lee, Jason Lester, Keith Kerr, Salli Muller, Natasha Iles, Sean Smith, Nirupa Murugaesu, Richard Mitter, Max Salm, Aengus Stuart, Nik Matthews, Haydn Adams, Tanya Ahmad, Richard Attanoos, Jonathan Bennett, Nicolai Juul Birkbak, Richard Booton, Ged Brady, Keith Buchan, Arrigo Capitano, Mahendran Chetty, Mark Cobbold, Philip Crosbie, Helen Davies, Alan Denison, Madhav Djearman, Jacki Goldman, Tom Haswell, Leena Joseph, Malgorzata Kornaszewska, Matthew Krebs, Gerald Langman, Mairead MacKenzie, Joy Millar, Bruno Morgan, Babu Naidu, Daisuke Nonaka, Karl Peggs, Catrin Pritchard, Hardy Remmen, Andrew Rowan, Rajesh Shah, Elaine Smith, Yvonne Summers, Magali Taylor, Selvaraju Veeriah, David Waller, Ben Wilcox, Maggie Wilcox, Ian Woolhouse, Nicholas McGranahan, Charles Swanton
Publikováno v:
PLoS Biology, Vol 12, Iss 7, p e1001906 (2014)
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an
Externí odkaz:
https://doaj.org/article/8c969701acb64396b9868a4b3806e9e1
Autor:
Richard Booton, Matthew Evison, David R Baldwin, Neal Navani, Ian Woolhouse, Lonny Yarmus, Mohammed Munavvar, Andrea Bianco, Syeda Jafri, Sam M. Janes, Mohamed Elshafi, Matthew Nankivell, J.B. Adizie, Usman Maqsood, Fabio Perrotta, Andrew D. Lerner, Keith M. Kerr
Publikováno v:
Chest. 158:1230-1239
Background: Programmed death-ligand 1 (PD-L1) expression on cancer cells is a clinically important biomarker to select patients with non-small cell lung cancer (NSCLC) for treatment with programmed death-1/PD-L1 inhibitors. Clinical trials of immunot
Autor:
Laila J. Tata, Andrew Wilcock, Richard Hubbard, Paul Beckett, Vanessa Beattie, Yvonne Nartey, Aamir Khakwani, Ian Woolhouse, Iain A. Stewart
Publikováno v:
Lung Cancer. 140:27-34
Objectives Healthcare systems increasingly recognise the importance of service users’ perspectives for improving care organisation and delivery. The English Cancer Patient Experience Survey (CPES) is carried out annually, however, its representativ
Publikováno v:
Clinical Oncology. 31:688-696
Aims We present the first analysis of the management and outcomes of stage III non-small cell lung cancer (NSCLC) conducted in England using National Lung Cancer Audit data. Materials and methods Patients diagnosed with stage III NSCLC in 2016 were i
Autor:
Richard Hubbard, Aamir Khakwani, Andrew Wilcock, Ian Woolhouse, Yvonne Nartey, Vanessa Beattie, Iain A. Stewart, Paul Beckett, Laila J. Tata
Publikováno v:
Pleural and mediastinal malignancies.
Introduction: More than 2,700 people are diagnosed with mesothelioma each year in the UK. We assessed whether the English Cancer Patient Experience Survey (CPES) respondents with mesothelioma were representative of all people diagnosed with mesotheli
Autor:
Ian Woolhouse, Neal Navani, Jana Bhavani Adizie, Richard Hubbard, Paul Beckett, Susan Harden, Aamir Khakwani
Publikováno v:
Thorax. 74:546-550
IntroductionData from the National Lung Cancer Audit (NLCA) often show variation in outcomes between lung cancer units which are not entirely explained by case mix. We explore the association between the organisation of services and patient outcome.M
Autor:
Tanya Pankhurst, Michael J. Berry, Simon Ball, Peter Nightingale, Suzy Gallier, Alexander Topham, Ian Woolhouse, Mark Garrick, Elizabeth Sapey
Publikováno v:
SSRN Electronic Journal.
BACKGROUNDVenous thromboembolism (VTE) causes significant mortality and morbidity in hospitalised patients. In England, reporting the percentage of patients with a completed VTE risk assessment is mandated, but this does not include whether that risk